36TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 Editorial team 24/7 BIOPHARMA capabilities that ensure consistent efficacy and safety in each batch is further underscored by the variability between ADC products in the development pipeline. CDMOs can provide their clients with the insight needed to quickly establish the necessary occupational exposure limits (OELs) and storage protocols, as well as conduct a rigorous risk and containment evaluation. Supporting ADC programs with capacity-solutions With a global network and team of highly experienced scientists, Veranova has the technical ability to unlock the potential of ADCs. Our skilled process chemists and analytical scientists possess over a decade of experience in the development and scale up of linker molecules for antibody-drug conjugates (ADCs), including several years of experience in polymer drug conjugates and other drug delivery applications. We empower ADC programs with leading expertise, flexible manufacturing, and seamless commercialization, advancing ADCs from Phase 2 to market with flexible, scalable capacity. Looking toward a bright future Possessing the power to target diseased cells while minimizing side effects, ADCs are set to increase in popularity over the coming years. Moreover, as the industry’s chemical understanding expands, the application of ADCs is likely to spill into areas beyond oncology. For example, ADCs are predicted to demonstrate therapeutic potential in the treatment of immunological disorders, kidney failure, and arthritis.3 In order to usher in the next wave of ADC successes, an integrated strategy that incorporates meticulous target selection, chemical fine-tuning, and stringent safety protocols will be essential. This comprehensive approach, enabled by strategic partnerships with expert CDMOs such as Veranova, is paving the way for ADC development and deployment. As these innovative therapeutics gain momentum, the result will be a significant positive impact on the pharmaceutical landscape and patients alike. References 1. Grand View Research. Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 – 2030. 2023. https://www. grandviewresearch.com/industry-analysis/ antibody-drug-conjugates-market 2. Grairi, M. and Le Borgne, M. Antibody-drug Conjugates: prospects for the next generation. Drug Discovery Today 2024, 29, 12. https://doi. org/10.1016/j.drudis.2024.10424 3. Pal, L.B., Bule, P., Khan, W., Chella, N. An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications. Pharmaceutics 2023, 15, 1807. https://doi.org/10.3390/pharmaceutics15071807 VERANOVA Figure 3. Partnering with a CDMO that can provide bespoke method development and process characterization ensures smooth ADC scale up.
RkJQdWJsaXNoZXIy MjY2OTA4MA==